Status:
COMPLETED
A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer
Lead Sponsor:
Arcus Biosciences, Inc.
Collaborating Sponsors:
Gilead Sciences
Conditions:
Healthy Participants
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This study will assess absorption, metabolism, and excretion of Radioactively Labeled Etrumadenant in healthy volunteers.
Eligibility Criteria
Inclusion
- BMI between 18.0 to 32.0 kg/m2
- Body weight ≥50 kg
- Good physical and mental health on the basis of medical history, physical examination, clinical laboratory, ECG, and vital signs, as judged by the Investigator.
- All clinical laboratory test results within the normal range or showing no clinically relevant deviations as judged by the Investigator.
- Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from (first) admission to the clinical research center until 90 days after the study drug administration. Adequate contraception for the male subject (and his female partner, if she is of childbearing potential) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence from heterosexual intercourse, in accordance with the lifestyle of the subject, is also acceptable.
Exclusion
- Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines \[including ecstasy\], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening or admission to the clinical research center.
- Significant and/or acute illness within 5 days prior to drug administration that may impact safety assessments, in the opinion of the Investigator.
- Irregular defecation pattern (less than once per 2 days).
- For a study with a radiation burden of superior to 0.1 mSv, the subject will be excluded if he participated in another study with a radiation burden of superior to 0.1 mSv and inferior or equal to 1 mSv in the period of 1 year prior to screening; a radiation burden of superior to 1.1 mSv and inferior or equal 2 mSv in the period of 2 years prior to screening; a radiation burden of superior to 2.1 mSv and inferior or equal 3 mSv in the period of 3 years prior to screening.
- Exposure to radiation for diagnostic reasons (except dental X rays and plain X rays of thorax and bony skeleton \[excluding spinal column\]), during work, or during participation in a clinical study in the period of 1 year prior to screening.
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 7 2022
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT05411146
Start Date
May 25 2022
End Date
July 7 2022
Last Update
May 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA Health Sciences (PRA) - Early Development Services (EDS)
Groningen, NZ, Netherlands, 9728